Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n-acetyl-8-methoxycoumarin-3-carboxamide
- Development stage
- Preclinical
- Lead developer
- Shaqra University
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Subcutaneous, Intranasal, Sublingual, Buccal, Topical, Transdermal, Intraperitoneal, Rectal, Intravenous, Intradermal, Acupoint
01
Overview
N-acetyl-8-methoxycoumarin-3-carboxamide is a small molecule research compound belonging to the 8-methoxycoumarin-3-carboxamide class. It was synthesized through the acetylation of 8-methoxycoumarin-3-carboxamide and has demonstrated antiproliferative activity against HepG2 liver cancer cells with an IC50 of 2.3 µM. The compound shows improved cytotoxic activity compared to its parent scaffold, suggesting that the acetyl group enhances binding to target proteins, likely through hydrogen bonding. Mechanistically, this class of compounds is designed to inhibit β-tubulin polymerization and activate caspase-3/7 mediated apoptosis. It is currently an academic research compound primarily studied for its potential in treating hepatocellular carcinoma.
- Other names
- N-acetyl-8-methoxycoumarin-3-carboxamideN-acetyl8-methoxycoumarin-3-carboxamideN-acetyl 8-methoxycoumarin-3-carboxamideN-(acetyl)8-methoxycoumarin-3-carboxamide
02
Targets
CASP3 (Caspase-3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on n-acetyl-8-methoxycoumarin-3-carboxamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on n-acetyl-8-methoxycoumarin-3-carboxamide.